clobazam (ONFI, Frisium, Urbanol)
Jump to navigation
Jump to search
Indications
- adjunctive therapy for seizures associated with Lennox-Gastaut syndrome in patients >= 2 years of age
Dosage
oral
Tabs: 5, 10, & 20 mg
Pharmacokinetics
- elimination 1/2 life of 18 hours
Adverse effects
- sedation, dizziness, constipation[5]
- tolerance, pyrexia
- Stevens-Johnson syndrome (SJS)[5]
- toxic epidermal necrolysis (TEN)[4] (rare)
- benzodiazepine withdrawal[5]
- drug adverse effects of benzodiazepines
- drug adverse effects of psychotropic agents
- drug adverse effects of sedatives
Mechanism of action
- thought to involve potentiation of GABAergic neurotransmission resulting from binding at the benzodiazepine site of the GABA-A receptor
More general terms
References
- ↑ Business Wire: Oct 24, 2011 FDA Approves ONFI<TM> (clobazam) for the Adjunctive Treatment of Seizures Associated with Lennox-Gastaut Syndrome in Patients Two Years and Older http://www.businesswire.com/news/home/20111024005933/en/FDA-Approves-ONFI%E2%84%A2-clobazam-Adjunctive-Treatment-Seizures
- ↑ Wikipedia: Clobazam http://en.wikipedia.org/wiki/Clobazam
- ↑ Hanks GW Clobazam: Pharmacological and therpeutic profile Br J Clin Pharmacol. 1979; 7(Suppl 1): 151S-155S http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1429523/
- ↑ 4.0 4.1 FDA Drug Safety Communication: 12-3-2013 FDA warns of serious skin reactions with the anti-seizure drug Onfi (clobazam) and has approved label changes. http://www.fda.gov/Drugs/DrugSafety/ucm377204.htm
- ↑ 5.0 5.1 5.2 5.3 Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015